Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
According to the latest research, the global Ranibizumab market size was valued at USD 2730.92 million in 2022 and is expected to expand at a CAGR of 3.75% during the forecast period, reaching USD 3406.85 million by 2028.
Ranibizumab is a monoclonal antibody fragment obtained from bevacizumab from the same parental murine antibody. It is much smaller than the parent molecule and binds more tightly to vascular endothelial growth factor-A. It is an angiogenesis inhibitor that has been approved for the treatment of "wet" age-related macular degeneration.
Strength
Development of economy and technology.
The product has obvious efficacy and excellent quality.
The increase in the number of people with eye diseases has brought a lot of demand.
Weakness
High R&D expenses in the early stage and high technical content.
Regional development is uneven, many regions are underdeveloped, and the market is narrow.
Opportunity
Exchanges and cooperation between suppliers deepen.
Growing opportunities in emerging markets, such as China, Japan.
Threat
The impact of trade war.
Government control will be more strict.
Threat from alternatives.
Region Overview:
North America is projected to account for a considerable share of the Ranibizumab market and is expected to become the largest region by 2028.
Company Overview:
Novartis is one of the major players operating in the Ranibizumab market, holding a share of 55.71% in 2021.
Novartis
Novartis is a pharmaceutical and biotechnology multinational company headquartered in Basel, Switzerland. Its core business is in the fields of patents, consumer health, generics, eye care and animal health. Novartis was founded in 1996 by the merger of two chemical and pharmaceutical companies in Basel, Ciba-Geigy and Sandoz.
Genentech
Genentech is a scientifically innovative research-oriented company with more than 1,100 researchers, scientists, and post-graduate students who conduct a wide range of scientific research and development – from molecular biology to protein chemistry to bioinformatics and physiology. Scientists in different fields of Genentech now target five disease categories: oncology, immunology, tissue growth and repair, neuroscience and infectious diseases.
Segmentation Overview:
As for product types, the Single-use Glass Vial segment held the largest market share in 2022.
Application Overview:
By application, the wAMD segment occupied the biggest share from 2018 to 2022.
wAMD
wAMD is characterized by sudden loss of monocular vision, distortion of the subject or central dark spots, and the other eye may appear symptoms after a longer period of time. Subretinal hemorrhage and exudation in the posterior pole of the fundus, sometimes with gray-yellow lesions, which may be neovascularization.
Diabetic Retinopathy (DR)
Diabetic retinopathy is the result of chronic progressive retinal microvascular leakage and obstruction caused by diabetes. To some extent, all diabetic patients will eventually have this change.
Diabetic Macular Edema (DME)
Diabetic macular edema (DME) refers to retinal thickening or hard exudation deposition caused by the accumulation of extracellular fluid in the foveal diameter of the macula due to diabetes.
mCNV
Myopic choroidal neovascularization refers to proliferating blood vessels from the choroidal capillaries that extend through the rupture of the Bruch membrane, between the Bruch membrane and the retinal pigment epithelium, or between the neural retina and the retinal pigment epithelium, or between the retinal pigment epithelium and the choroid. Proliferation, many diseases involving the RPE-Bruch membrane-choroidal capillary complex can lead to the formation of CNV, also known as subretinal neovascularization.
RVO
Retinal vein occlusion is a common fundus vascular disease. Retinal vein occlusion (RVO) is a common high-blind retinal vascular disease that affects the main complication of vision in patients with macular edema (ME).
This report elaborates on the market size, market characteristics, and market growth of the Ranibizumab industry between the year 2018 to 2028, and breaks down according to the product type, downstream application, and consumption area of Ranibizumab. The report also introduces players in the industry from the perspective of the value chain and looks into the leading companies.
Key Points this Global Ranibizumab Market Report Include:
Market Size Estimates: Ranibizumab market size estimation in terms of revenue and sales from 2018-2028
Market Dynamic and Trends: Ranibizumab market drivers, restraints, opportunities, and challenges
Macro-economy and Regional Conflict: Influence of global inflation and Russia & Ukraine War on the Ranibizumab market
Segment Market Analysis: Ranibizumab market revenue and sales by type and by application from 2018-2028
Regional Market Analysis: Ranibizumab market situations and prospects in major and top regions and countries
Ranibizumab Market
Ranibizumab Industry Chain: Ranibizumab market raw materials & suppliers, manufacturing process, distributors by region, downstream customers
Ranibizumab Industry News, Policies by regions
Ranibizumab Industry Porters Five Forces Analysis
Key players in the global Ranibizumab market are covered in Chapter 2:
Novartis
Genentech
In Chapter 6 and Chapter 9, on the basis of types, the Ranibizumab market from 2018 to 2028 is primarily split into:
Single-use Prefilled Syringe
Single-use Glass Vial
In Chapter 7 and Chapter 10, on the basis of applications, the Ranibizumab market from 2018 to 2028 covers:
wAMD
Diabetic Retinopathy (DR)
Diabetic Macular Edema (DME)
mCNV
RVO
Geographically, the detailed analysis of consumption, revenue, market share and growth rate of the following regions from 2018 to 2028 are covered in Chapter 8 and Chapter 11:
United States
Europe
China
Japan
India
Southeast Asia
Latin America
Middle East and Africa
Others
In summary, this report relies on sources from both primary and secondary, combines comprehensive quantitative analysis with detailed qualitative analysis, and pictures the market from a macro overview to micro granular segment aspects. Whatever your role in this industry value chain is, you should benefit from this report with no doubt.
Chapter Outline
This report consists of 12 chapters. Below is a brief guideline to help you quickly grasp the main contents of each chapter:
Chapter 1 first introduces the product overview, market scope, product classification, application, and regional division, and then summarizes the global Ranibizumab market size in terms of revenue, sales volume, and average price.
Chapter 2 analyzes the main companies in the Ranibizumab industry, including their main businesses, products/services, sales, prices, revenue, gross profit margin, and the latest developments/updates.
Chapter 3 is an analysis of the competitive environment of Ranibizumab market participants. This mainly includes the revenue, sales, market share, and average price of the top players, along with the market concentration ratio in 2022 and the players' M&A and expansion in recent years.
Chapter 4 is an analysis of the Ranibizumab industrial chain, including raw material analysis, manufacturing cost structure, distributors, and major downstream buyers.
Chapter 5 focuses on Ranibizumab market dynamics and marketing strategy analysis, which include opportunities, challenges, industry development trends under inflation, industry news and policies analyzed by region, Porter's Five Forces analysis, as well as direct and indirect marketing, and the development trends of marketing channels.
Chapters 6-8 have segmented the Ranibizumab market by type, application, and region, with a focus on sales and value from 2018 to 2023 from both vertical and horizontal perspectives.
Chapters 9-11 provide detailed Ranibizumab market forecast data for 2023-2028, broken down by type and application, region, and major countries to help understand future growth trends.
Chapter 12 concludes with an explanation of the data sources and research methods. Verify and analyze through preliminary research to obtain final quantitative and qualitative data.
2022
Ranibizumab is a monoclonal antibody fragment obtained from bevacizumab from the same parental murine antibody. It is much smaller than the parent molecule and binds more tightly to vascular endothelial growth factor-A. It is an angiogenesis inhibitor that has been approved for the treatment of "wet" age-related macular degeneration.
Strength
Development of economy and technology.
The product has obvious efficacy and excellent quality.
The increase in the number of people with eye diseases has brought a lot of demand.
Weakness
High R&D expenses in the early stage and high technical content.
Regional development is uneven, many regions are underdeveloped, and the market is narrow.
Opportunity
Exchanges and cooperation between suppliers deepen.
Growing opportunities in emerging markets, such as China, Japan.
Threat
The impact of trade war.
Government control will be more strict.
Threat from alternatives.
Region Overview:
North America is projected to account for a considerable share of the Ranibizumab market and is expected to become the largest region by 2028.
Company Overview:
Novartis is one of the major players operating in the Ranibizumab market, holding a share of 55.71% in 2021.
Novartis
Novartis is a pharmaceutical and biotechnology multinational company headquartered in Basel, Switzerland. Its core business is in the fields of patents, consumer health, generics, eye care and animal health. Novartis was founded in 1996 by the merger of two chemical and pharmaceutical companies in Basel, Ciba-Geigy and Sandoz.
Genentech
Genentech is a scientifically innovative research-oriented company with more than 1,100 researchers, scientists, and post-graduate students who conduct a wide range of scientific research and development – from molecular biology to protein chemistry to bioinformatics and physiology. Scientists in different fields of Genentech now target five disease categories: oncology, immunology, tissue growth and repair, neuroscience and infectious diseases.
Segmentation Overview:
As for product types, the Single-use Glass Vial segment held the largest market share in 2022.
Application Overview:
By application, the wAMD segment occupied the biggest share from 2018 to 2022.
wAMD
wAMD is characterized by sudden loss of monocular vision, distortion of the subject or central dark spots, and the other eye may appear symptoms after a longer period of time. Subretinal hemorrhage and exudation in the posterior pole of the fundus, sometimes with gray-yellow lesions, which may be neovascularization.
Diabetic Retinopathy (DR)
Diabetic retinopathy is the result of chronic progressive retinal microvascular leakage and obstruction caused by diabetes. To some extent, all diabetic patients will eventually have this change.
Diabetic Macular Edema (DME)
Diabetic macular edema (DME) refers to retinal thickening or hard exudation deposition caused by the accumulation of extracellular fluid in the foveal diameter of the macula due to diabetes.
mCNV
Myopic choroidal neovascularization refers to proliferating blood vessels from the choroidal capillaries that extend through the rupture of the Bruch membrane, between the Bruch membrane and the retinal pigment epithelium, or between the neural retina and the retinal pigment epithelium, or between the retinal pigment epithelium and the choroid. Proliferation, many diseases involving the RPE-Bruch membrane-choroidal capillary complex can lead to the formation of CNV, also known as subretinal neovascularization.
RVO
Retinal vein occlusion is a common fundus vascular disease. Retinal vein occlusion (RVO) is a common high-blind retinal vascular disease that affects the main complication of vision in patients with macular edema (ME).
This report elaborates on the market size, market characteristics, and market growth of the Ranibizumab industry between the year 2018 to 2028, and breaks down according to the product type, downstream application, and consumption area of Ranibizumab. The report also introduces players in the industry from the perspective of the value chain and looks into the leading companies.
Key Points this Global Ranibizumab Market Report Include:
Market Size Estimates: Ranibizumab market size estimation in terms of revenue and sales from 2018-2028
Market Dynamic and Trends: Ranibizumab market drivers, restraints, opportunities, and challenges
Macro-economy and Regional Conflict: Influence of global inflation and Russia & Ukraine War on the Ranibizumab market
Segment Market Analysis: Ranibizumab market revenue and sales by type and by application from 2018-2028
Regional Market Analysis: Ranibizumab market situations and prospects in major and top regions and countries
Ranibizumab Market
Competitive Landscape
and Major Players: Analysis of 10-15 leading market players, sales, price, revenue, gross, gross margin, product/service profile and recent development/updates, etc.Ranibizumab Industry Chain: Ranibizumab market raw materials & suppliers, manufacturing process, distributors by region, downstream customers
Ranibizumab Industry News, Policies by regions
Ranibizumab Industry Porters Five Forces Analysis
Key players in the global Ranibizumab market are covered in Chapter 2:
Novartis
Genentech
In Chapter 6 and Chapter 9, on the basis of types, the Ranibizumab market from 2018 to 2028 is primarily split into:
Single-use Prefilled Syringe
Single-use Glass Vial
In Chapter 7 and Chapter 10, on the basis of applications, the Ranibizumab market from 2018 to 2028 covers:
wAMD
Diabetic Retinopathy (DR)
Diabetic Macular Edema (DME)
mCNV
RVO
Geographically, the detailed analysis of consumption, revenue, market share and growth rate of the following regions from 2018 to 2028 are covered in Chapter 8 and Chapter 11:
United States
Europe
China
Japan
India
Southeast Asia
Latin America
Middle East and Africa
Others
In summary, this report relies on sources from both primary and secondary, combines comprehensive quantitative analysis with detailed qualitative analysis, and pictures the market from a macro overview to micro granular segment aspects. Whatever your role in this industry value chain is, you should benefit from this report with no doubt.
Chapter Outline
This report consists of 12 chapters. Below is a brief guideline to help you quickly grasp the main contents of each chapter:
Chapter 1 first introduces the product overview, market scope, product classification, application, and regional division, and then summarizes the global Ranibizumab market size in terms of revenue, sales volume, and average price.
Chapter 2 analyzes the main companies in the Ranibizumab industry, including their main businesses, products/services, sales, prices, revenue, gross profit margin, and the latest developments/updates.
Chapter 3 is an analysis of the competitive environment of Ranibizumab market participants. This mainly includes the revenue, sales, market share, and average price of the top players, along with the market concentration ratio in 2022 and the players' M&A and expansion in recent years.
Chapter 4 is an analysis of the Ranibizumab industrial chain, including raw material analysis, manufacturing cost structure, distributors, and major downstream buyers.
Chapter 5 focuses on Ranibizumab market dynamics and marketing strategy analysis, which include opportunities, challenges, industry development trends under inflation, industry news and policies analyzed by region, Porter's Five Forces analysis, as well as direct and indirect marketing, and the development trends of marketing channels.
Chapters 6-8 have segmented the Ranibizumab market by type, application, and region, with a focus on sales and value from 2018 to 2023 from both vertical and horizontal perspectives.
Chapters 9-11 provide detailed Ranibizumab market forecast data for 2023-2028, broken down by type and application, region, and major countries to help understand future growth trends.
Chapter 12 concludes with an explanation of the data sources and research methods. Verify and analyze through preliminary research to obtain final quantitative and qualitative data.
Years considered for this report:
Historical Years:
2018-2022Base Year:
2022Estimated Year:
2023Forecast Period:
2023-2028Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
